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ABSTRACT: Transition metal complexes provide a promising avenue for the design of therapeutic and
diagnostic agents, but the limited understanding of their cellular uptake is a roadblock to their effective
application. Here, we examine the mechanism of cellular entry of a luminescent ruthenium(II) polypyridyl
complex, Ru(DIP)2dppz2+ (where DIP ) 4,7-diphenyl-1,10-phenanthroline and dppz ) dipyridophenazine),
into HeLa cells, with the extent of uptake measured by flow cytometry. No diminution of cellular uptake
is observed under metabolic inhibition with deoxyglucose and oligomycin, indicating an energy-independent
mode of entry. The presence of organic cation transporter inhibitors also does not significantly alter uptake.
However, the cellular internalization of Ru(DIP)2dppz2+ is sensitive to the membrane potential. Uptake
decreases when cells are depolarized with high potassium buffer and increases when cells are hyperpolarized
with valinomycin. These results support passive diffusion of Ru(DIP)2dppz2+ into the cell.
Transition metal complexes have tremendous potential as
diagnostic and therapeutic agents. They can be exploited for
their modularity, reactivity, imaging capabilities, redox
chemistry, and precisely defined three-dimensional structure.
An increasing number of biological applications have been
explored (1-3). Complexes that are currently in clinical use
include the platinum anticancer drugs, radiodiagnostic agents
containing 99mTc, and gadolinium(III) magnetic resonance
imaging contrast agents.
In order to design new metal-based drugs more rationally,
an understanding of the physiological processing of metal
complexes is required. Though cellular uptake is critical to
the success of a drug or probe, few mechanistic details are
known regarding metal complex uptake. Different entry
mechanisms may be preferred depending on the application,
as the mode of entry affects cell-type specificity, the rate of
internalization, and the fate of the compound once inside
the cell. For example, entry by diffusion affords broad cell-
type specificity, a great advantage in the use of fluorescent
probes for live cell imaging. Conversely, medicinal chemists
may seek to deliver drugs to target organs, taking advantage
of tissue-specific transporters (4) or receptors (5). For each
mode of entry, there are also drawbacks. With protein-
mediated transport, the degree of modification of the
molecule is limited because transport relies on recognition.
With endocytosis, molecules are often trapped in endosomes
and face degradation by lysosomal enzymes.
Ruthenium(II) polypyridyl complexes are useful for study-
ing cellular uptake due to their facile synthesis, stability in
aqueous solution, and luminescence. Using confocal micros-
copy and flow cytometry, we have examined the uptake of
a series of dipyridophenazine (dppz)1 complexes of ruthe-
nium (6). Despite its larger size, the lipophilic Ru(DIP)2-
dppz2+, where DIP ) 4,7-diphenyl-1,10-phenanthroline,
illustrated in Figure 1, accumulates in cells more quickly
than Ru(bpy)2dppz2+ (where bpy ) 2,2′-bipyridine) and
Ru(phen)2dppz2+ (where phen ) 1,10-phenanthroline).
Ru(DIP)2dppz2+ enters cells within an hour at micromolar
concentrations, providing a reasonable time window for
uptake experiments. Details of the cellular uptake mechanism
of Ru(DIP)2dppz2+ can then be applied to understanding
uptake characteristics of other structurally similar cationic
metal complexes.
The biological activity of ruthenium complexes was first
examined by Francis Dwyer in the 1950s, where a full family
of tris(polypyridyl) complexes was shown to have bacterio-
static and antiviral activities (7). More recently, many
ruthenium complexes have been tested for therapeutic
potential (8), and two ruthenium anticancer drugs (NAMI-A
and KP1019) have reached clinical trials (9, 10). Cellular
uptake of some ruthenium(III) complexes appears to be
mediated by the iron transport protein transferrin. KP1019
(indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)])
binds transferrin with displacement of a chloride ligand and
is transported into cells with transferrin by receptor-mediated
endocytosis (5). Ruthenium complexes lacking a labile ligand
such as chloride are unlikely to be able to enter cells in this
manner, and their mechanism of entry has not been established.
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Such coordinatively saturated tris(chelate) ruthenium
complexes furthermore serve as close fluorescent analogues
of rhodium complexes that we have explored as potential
chemotherapeutic agents (11). These lipophilic, cationic
rhodium complexes target single base mismatches in DNA
and selectively inhibit cellular proliferation in mismatch
repair-deficient cell lines (3).
The main routes into a cell are endocytosis, active
transport, facilitated diffusion, and passive diffusion. Due
to its lipophilicity and positive charge, Ru(DIP)2dppz2+ likely
traverses the membrane in response to the membrane
potential, similar to other lipophilic cations such as tetraphe-
nylphosphonium and rhodamine 123 (12, 13). Here, we use
chemical tools to elucidate the cellular uptake mechanism
of Ru(DIP)2dppz2+, with the degree of uptake analyzed by
flow cytometry.
EXPERIMENTAL PROCEDURES
Materials. Cell culture reagents, transferrin-AlexaFluor488
conjugate, and To-Pro-3 were purchased from Invitrogen.
Oligomycin, deoxyglucose, and the cation transporter inhibi-
tors were obtained from Aldrich. Valinomycin was purchased
from Calbiochem.
Synthesis of Ru Complexes. Ru(DIP)2dppz2+ and Ru(phen)2-
dppz2+ were synthesized as described previously (6). Briefly,
Ru(DIP)2Cl2 and Ru(phen)2Cl2 were synthesized in an
analogous fashion to Ru(bpy)2Cl2 (14). The dipyridophena-
zine (dppz) ligand was synthesized as previously described
(15) and added to RuL2Cl2 by refluxing in ethanol-water
for >3 h to make Ru(DIP)2dppz2+ and Ru(phen)2dppz2+. The
ethanol was removed by rotary evaporation, resulting in
precipitation of [Ru(DIP)2dppz]Cl2, which was collected by
filtration. Ru(phen)2dppz2+ was precipitated as the hexafluo-
rophosphate salt and then returned to the chloride salt by a
Sephadex DEAE anion-exchange column. The Ru complexes
utilized are racemic mixtures of the two enantiomers.
Cell Culture. HeLa cells (ATCC, CCL2) were maintained
in minimal essential medium R with 10% fetal bovine serum
and 1% penicillin-streptomycin (100×).
InductiVely Coupled Plasma Mass Spectrometric (ICP-
MS) Detection of Ru. HeLa cells were grown to ∼30%
confluency in 75 cm2 flasks and incubated with 5 µM
Ru(DIP)2dppz2+ for 1 h at 37 °C in either media with serum or
media without serum. The solution from the serum-free incuba-
tion was saved for circular dichroism measurements (described
below). The cells were rinsed with PBS, detached with trypsin,
and counted. The cells were isolated by centrifugation and
digested in concentrated nitric acid for 1.5 h at 60 °C. The
solution was diluted with Millipore water to 2.0 mL for the
incubation with serum and 20.0 mL for the serum-free incuba-
tion, adding nitric acid to give 2%. The Ru content was
measured using a Hewlett-Packard 4500 ICP-MS. Data are
reported as the mean ( the standard deviation (n ) 3).
Assay of Enantiomeric Preference in Ru Uptake. HeLa
cells were grown to ∼30% confluency in 75 cm2 flasks and
incubated with 5 µM Ru(DIP)2dppz2+ for 1 h at 37 °C in
media without serum and phenol red. After incubation, the
media were retrieved from the flask. The Ru complex was
purified from the media using a Waters C18 Sep-Pak. The
solution was loaded onto a 1 g Sep-Pak equilibrated with
water. The Sep-Pak was then rinsed with 150 mL of water
and 15 mL of 20/80 CH3CN/H2O with 0.1% TFA. The Ru
complex was eluted with 90/10 CH3CN/H2O with 0.1% TFA
and lyophilized. For circular dichroism (CD) measurements,
this isolated complex was dissolved in CH3CN to give 8 µM
complex. CD spectra were recorded on an AVIV 62 CD
spectrometer.
Metabolic Inhibition. HeLa cells were detached from
culture and treated with either 50 mM 2-deoxy-D-glucose
and 5 µM oligomycin in PBS (to inhibit cellular metabolism)
or 5 mM glucose in PBS for 1 h at 37 °C. Both solutions
also contained 2.5 mg/mL bovine serum albumin fraction V
(BSAV). The cells were then rinsed and suspended in either
PBS with BSAV for the inhibition cells or PBS with BSAV
and 5 mM glucose for the control cells. The cells were
incubated with 10 mg/L transferrin-AlexaFluor488 or 5 µM
Ru(DIP)2dppz2+ for 1 h at 37 °C. Following incubation, the
transferrin-treated cells were rinsed with PBS and trypsinized
to cleave the transferrin receptors from the cell surface (16).
The Ru-treated cells were rinsed. The cells were analyzed
by flow cytometry. Ru-treated cells were not trypsinized
following incubation, as rinsed cells and trypsinized cells
gave the same mean luminescence in a control experiment:
282 ( 18 for the rinsed cells and 284 ( 23 for the trypsinized
cells, following a 1 h incubation at 37 °C with 5 µM
Ru(DIP)2dppz2+.
Temperature Dependence of Uptake. HeLa cells were
detached from culture and washed with Hanks’ balanced salt
FIGURE 1: A luminescent ruthenium probe used to examine metal
complex uptake. Top: Chemical structure of Ru(DIP)2dppz2+.
Bottom: HeLa cells incubated with 5 µM Ru(DIP)2dppz2+ for 4 h,
imaged by confocal microscopy. Note that the cytoplasm is
extensively stained with the Ru complex. Scale bar is 10 µm.
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solution (HBSS) supplemented with 2.5 mg/mL BSAV. The
cells were incubated with 5 µM Ru(DIP)2dppz2+ or
Ru(phen)2dppz2+ for 2 h, or 10 mg/L transferrin-Alexa488
for 1 h, in HBSS with BSAV at 4 °C, ambient temperature
(20-23 °C), or 37 °C. Transferrin-treated cells were
trypsinized following incubation. The amount of uptake was
analyzed by flow cytometry.
Cation Transporter Inhibition. HeLa cells were detached
from culture and washed with buffer (HBSS supplemented
with BSAV) and then pretreated for 20 min with either 1
mM cation transport inhibitor or buffer only. The cells were
then incubated with 5 µM Ru(DIP)2dppz2+ for 1 h at ambient
temperature. The cells were rinsed with buffer, and Ru uptake
was analyzed by flow cytometry.
Modulation of Membrane Potential. HeLa cells were
detached from culture and washed three times with either
HBSS (containing 5.8 mM K+) or high K+-HBSS (containing
170 mM K+), both supplemented with 2.5 mg/mL BSAV.
Some of the cells in HBSS were pretreated with 50 µM
valinomycin for 30 min at 37 °C. The cells were incubated
with 2 µM Ru(DIP)2dppz2+ for 1 h at 37 °C in one of the
following solutions: HBSS, HBSS with valinomycin (to
hyperpolarize the cells), or high K+-HBSS (to depolarize the
cells). The solutions also contained BSAV. After incubation,
the cells were rinsed, and the extent of uptake was analyzed
by flow cytometry.
Flow Cytometry. Cells were detached from culture with
EDTA (0.48 mM in PBS) and incubated at 1 × 106 cells/
mL with Ru complex (added from a concentrated DMSO
stock) under conditions described above and then placed on
ice. To-Pro-3 was added at 1 µM immediately prior to flow
cytometry analysis to stain dead cells. The fluorescence of
∼20000 cells was measured using a BD FACS Aria, exciting
with the 488 nm laser for Ru and transferrin-AlexaFluor488
and with the 633 nm laser for To-Pro-3. Emission was
observed at 600-620 nm for Ru, 515-545 nm for Alex-
aFluor488, and 650-670 nm for To-Pro-3. Cells exhibiting
To-Pro-3 fluorescence were excluded from the data analysis.
Fluorescence data are reported as the mean ( the standard
deviation (n ) 3).
RESULTS
Strategy To Measure Uptake. The dipyridophenazine
(dppz) complexes of ruthenium serve as light switches for
nonaqueous environments, luminescing only when bound to
the hydrophobic regions of membranes, nucleic acids, and
other macromolecules (17, 18). If the Ru complex decom-
poses or ligand substitution occurs, the resulting complex
would no longer luminesce. Additionally, the ligands them-
selves are not luminescent. Accordingly, the characteristic
luminescence indicates that the complex once inside the cell
remains intact. We can use the luminescence of these
ruthenium complexes to track their cellular uptake in both
confocal microscopy and flow cytometry experiments. Con-
focal imaging confirms that Ru(DIP)2dppz2+ accumulates
inside the cell rather than associating solely at the membrane
surface, as seen in Figure 1 and previously (6). Ruthenium
luminescence is observed throughout the cytoplasm, though
mostly excluded from the nucleus. Flow cytometry, on the
other hand, enables the rapid measurement of ruthenium
luminescence intensity for multiple cell populations. Using
primarily flow cytometry, we can then explore the cellular
uptake mechanism of Ru(DIP)2dppz2+ by comparing the
ruthenium luminescence following different incubation
conditions.
ICP-MS Measurement of Ru Uptake. Inductively coupled
plasma mass spectrometry (ICP-MS) measurements were
performed to quantify the amount of Ru taken up by the
cell. HeLa cells were treated with 5 µM Ru(DIP)2dppz2+
for 1 h at 37 °C in media with or without serum. ICP-MS
measurements give 26.4 ( 6.3 amol of Ru per cell for the
incubation in media with serum and 677 ( 73 amol per cell
for the serum-free incubation. Assuming an average cell
volume of 1.7 pL (19) and that the complex is evenly
distributed throughout this volume, the Ru concentration in
the cell is approximately 16 µM for incubation with serum
and 398 µM for the serum-free incubation. These results
indicate substantial concentration of the complex within the
cell, with serum acting to attenuate the effective free
ruthenium complex available in solution.
Enantiomeric Preference in Uptake. As racemic Ru(DIP)2-
dppz2+ was used for uptake experiments, we considered
whether HeLa cells preferentially take in one enantiomer over
the other. To test for enantioselectivity associated with
uptake, we assayed for enantiomeric enrichment in the
supernatant. Following incubation of Ru(DIP)2dppz2+ with
HeLa cells in serum-free media, the Ru complex was
recovered from the media, and the circular dichroism (CD)
was examined. Serum-free media was used for the incubation
to remove any potential chiral bias created from interaction
of the complex with serum proteins. ICP-MS determination
of the Ru content of the cells confirms that a significant
amount of Ru (∼3% of the total) was taken in by the cells.
Given this depletion, we estimate that an enantiomeric
preference in uptake of 2.5:1 or greater would be detectable
above instrument noise. However, the CD spectra of
Ru(DIP)2dppz2+ after incubation with cells is within the level
of the noise. This absence in optical activity indicates that
any enantiomeric preference must be below this limit.
Energy-Dependent Uptake Mechanisms. Certain cellular
uptake routes are energy-dependent, such as endocytosis (20)
and active protein transport. These pathways are hindered
when cells are incubated at low temperature (4 °C instead
of 37 °C) or in ATP-depleted environments (e.g., from
metabolic poisons). To determine whether Ru(DIP)2dppz2+
enters cells by an energy-dependent process, the complex
was incubated with HeLa cells after ATP depletion by
deoxyglucose (a glucose analogue that inhibits glycolysis)
and oligomycin (an inhibitor of oxidative phosphorylation)
(21, 22). As transferrin is internalized by clathrin-mediated
endocytosis, fluorescently (AlexaFluor488) labeled transferrin
was used as a positive control. The cellular uptake of
Ru(DIP)2dppz2+ remains essentially unchanged when cells
are under metabolic inhibition, with a mean luminescence
of 659 ( 12 compared to 675 ( 10 for the cells not treated
with deoxyglucose and oligomycin (Figure 2). Thus
Ru(DIP)2dppz2+ appears to enter cells by an energy-
independent process. In contrast, metabolic inhibition dra-
matically reduces the endocytosis of transferrin, demonstrated
by the large decrease in the mean fluorescence from 3034
( 52 to 210 ( 5.
The temperature dependence of Ru(DIP)2dppz2+ uptake
was also explored. HeLa cells were incubated with the
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complex at 4 °C, ambient temperature (20-23 °C), and 37
°C (Figure 3). The mean Ru luminescence increases with
incubation temperature, from 589 ( 17 at 4 °C to 826 ( 71
at 37 °C. Given the lipophilicity of Ru(DIP)2dppz2+, the
increase in cellular uptake with temperature could also be
the result of improved solubility in buffer at higher temper-
atures. To test this hypothesis, the temperature dependence
of uptake was studied for a similar but more soluble complex,
Ru(phen)2dppz2+. In this case, the mean luminescence
remains roughly the same at the different incubation tem-
peratures, 133 ( 10 at 4 °C and 141 ( 3 at 37 °C. Transferrin
internalization was significantly more sensitive to tempera-
ture, with the mean fluorescence increasing from 480 ( 7
at 4 °C to 4071 ( 167 at 37 °C.
Effect of Organic Cation Transporter Inhibitors. Organ-
isms use polyspecific organic cation transporters (OCTs) for
the distribution of endogenous organic cations and the
absorption, distribution, and elimination of cationic drugs
and toxins (23). These transporters facilitate the diffusion
of structurally diverse compounds. OCT substrates are
typically organic cations and weak bases, though some
neutral compounds and anions are also transported. Expres-
sion of the OCTs varies by tissue type. The carnitine and
cation transporter OCTN2 has the most widespread tissue
distribution among the OCTs, and its expression has been
detected in some cancer cell lines, including HeLa (24).
Numerous compounds that inhibit OCT-mediated transport
have been identified. Procainamide inhibits across the OCT
family (including OCT1-3, OCTN1, and OCTN2). Tetra-
ethylammonium ion is translocated by most of the OCTs,
while other n-tetraalkylammonium salts inhibit OCT1 and
OCT2, and for some OCTN1 (25).
To investigate whether Ru(DIP)2dppz2+ crosses the mem-
brane using an organic cation transporter, uptake of
Ru(DIP)2dppz2+ in the presence of OCT inhibitors was
analyzed. HeLa cells were incubated with 1 mM inhibitor
for 20 min before addition of Ru(DIP)2dppz2+ for 1 h. For
OCTs, the IC50’s of the inhibitors used are generally less
than 1 mM. Procainamide has an IC50 of <3 mM and
cimetidine <2 mM for OCTN2. As shown in Figure 4, the
extent of uptake was analyzed by flow cytometry. Signifi-
cantly, the n-tetraalkylammonium salts and procainamide do
not appreciably alter the cellular uptake of Ru(DIP)2dppz2+.
Within error, the cells have a similar mean luminescence
intensity. The complex does not appear to use an organic
cation transporter for entry into HeLa cells.
Effect of Membrane Potential. The plasma membranes of
viable cells exhibit a membrane potential (-50 to -70 mV),
with the inside of the cell negative with respect to the outside
(26). As Ru(DIP)2dppz2+ carries a positive charge, uptake
may be driven by the potential difference across the cell
membrane. The membrane potential in animal cells depends
mainly on the K+ concentration gradient. Here, the potential
FIGURE 2: Flow cytometry measuring Ru incorporation used to
examine the effect of metabolic inhibition on Ru(DIP)2dppz2+
cellular uptake. HeLa cells were pretreated for 1 h with 50 mM
deoxyglucose (dGlc) and 5 µM oligomycin, then rinsed, and
incubated with 5 µM Ru(DIP)2dppz2+ or 10 mg/L transferrin-
AlexaFluor488 (Tf-Alexa488) for 1 h. Cells treated with inhibitors
(red) are compared to control cells (blue). Top: Ru(DIP)2dppz2+
uptake. Bottom: Transferrin-AlexaFluor488 uptake.
FIGURE 3: Effect of incubation temperature on Ru(DIP)2dppz2+
cellular uptake measured by flow cytometry. HeLa cells were
incubated with 5 µM Ru(DIP)2dppz2+ for 2 h at 4 °C, ambient
temperature (20-23 °C), or 37 °C.
FIGURE 4: Effect of organic cation transporter inhibitors on
Ru(DIP)2dppz2+ cellular uptake measured by flow cytometry. HeLa
cells were pretreated with 1 mM inhibitor for 20 min; then 5 µM
Ru(DIP)2dppz2+ was added for 1 h. Each data point is the mean (
the standard deviation of three samples.
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was reduced to close to zero by incubating the cells in buffer
with potassium concentration equivalent to that found
intracellularly (∼170 mM) (27). This high potassium buffer
(K+-HBSS) was created by replacing sodium salts with
equimolar potassium salts, while hyperpolarization of the
membrane was achieved by adding valinomycin to low
potassium buffer (HBSS) (28). Valinomycin is a cyclic
peptide that selectively shuttles potassium ions across the
membrane down the electrochemical potassium ion gradient,
and it increases the membrane potential by exporting
potassium from the cell.
Ru(DIP)2dppz2+ was incubated with HeLa cells for 1 h in
either HBSS, HBSS with valinomycin (hyperpolarizes), or
K+-HBSS (depolarizes). The amount of Ru complex uptake
was analyzed by flow cytometry (Figure 5). Depolarization
of the plasma membrane reduces the uptake of Ru(DIP)2-
dppz2+, decreasing the mean luminescence of the cells from
232 ( 5 to 154 ( 1. Conversely, hyperpolarization of the
membrane with valinomycin clearly promotes Ru complex
uptake, increasing the mean luminescence to 428 ( 13. These
results indicate that the positively charged complex is being
driven inside the cells at least in part by the membrane
potential.
DISCUSSION
Cellular uptake of small molecules can occur through
energy-dependent (endocytosis, active transport) and energy-
independent (facilitated diffusion, passive diffusion) pro-
cesses. Metabolic inhibitors deplete the cell of energy,
resulting in diminished uptake of molecules entering by
endocytosis and active transport. HeLa cells treated with the
metabolic inhibitors deoxyglucose and oligomycin show
greatly reduced uptake (over 10-fold) of fluorescently labeled
transferrin, which enters cells by endocytosis. On the other
hand, deoxyglucose and oligomycin treatment causes no
reduction of Ru(DIP)2dppz2+ cellular uptake, suggesting an
energy-independent mode of entry. In fact, the midpoint of
the luminescence intensity profile increases slightly in cells
facing metabolic inhibition, though the mean fluorescence
remains approximately the same. If Ru(DIP)2dppz2+ is
actively exported, this efflux would be slowed under energy
depletion and could explain the small increase. In contrast
with the metabolic inhibition data, Ru(DIP)2dppz2+ uptake
decreases slightly with lower temperature (4 °C versus 37
°C), consistent with energy-dependent transport. The differ-
ence is not as dramatic as for transferrin, however, whose
fluorescence changes 8-fold. Given that Ru(DIP)2dppz2+ is
poorly soluble in buffer, this change may be due to improved
solubility with temperature. Accordingly, a similar but more
soluble complex, Ru(phen)2dppz2+, shows constant uptake
at different temperatures. Low temperature also increases
membrane viscosity, via decreased membrane fluidity, which
can impair diffusion through the membrane.
The possible role of an organic cation transporter (OCT)
in translocation of Ru(DIP)2dppz2+ across the membrane was
also explored. These transporters facilitate the diffusion of
endogenous organic cations as well as a variety of drugs
and toxins. Ru(DIP)2dppz2+ uptake is not significantly altered
in cells coincubated with OCT inhibitors, indicating that the
complex is likely not an OCT substrate. This result is
consistent with the large size of Ru(DIP)2dppz2+ (∼20 Å
diameter) compared to known OCT substrates.
The cellular uptake of Ru(DIP)2dppz2+ is, however,
influenced by the membrane potential. Consistent with
diffusion of a positively charged molecule, uptake increases
at higher potential and decreases at lower potential. That
severe metabolic impairment does not discourage complex
uptake is also consistent with diffusion. As both passage
through a channel or passive carrier and diffusion directly
through the lipid bilayer are energy-independent and respond
to changes in the membrane potential, other factors must be
considered to distinguish between these two mechanisms.
The ability of Ru(DIP)2dppz2+ to enter the cell despite cation
transporter inhibition, its larger size than typical transporter
substrates, and its relatively slow rate of cellular accumula-
tion implicate passive diffusion as the mechanism of entry.
Passive diffusion is less cell-type specific, allows greater
freedom for modification of the complex than transport via
membrane proteins, and does not lead to entrapment in
endosomes, as often occurs with endocytosis. As a result,
this mechanism of passive diffusion may portend the broad
applicability of metal complexes in different cell types for
different intracellular functions. Certainly these results
provide some basis for considering the biological activities
that have already been identified for cationic transition metal
complexes (3, 7). Significantly, knowledge of the mechanism
of cellular uptake of this ruthenium(II) polypyridyl complex
can now be applied to the design of structurally similar metal
complexes for therapeutic and diagnostic use.
ACKNOWLEDGMENT
We are grateful to the Caltech Flow Cytometry Facility
for expert assistance and facilities.
REFERENCES
1. Zhang, C. X., and Lippard, S. J. (2003) New metal complexes as
potential therapeutics. Curr. Opin. Chem. Biol. 7, 481–489.
2. Boerner, L. J. K., and Zaleski, J. M. (2005) Metal complex-DNA
interactions: from transcription inhibition to photoactivated cleav-
age. Curr. Opin. Chem. Biol. 9, 135–144.
3. Hart, J. R., Glebov, O., Ernst, R. J., Kirsch, I. R., and Barton,
J. K. (2006) DNA mismatch-specific targeting and hypersensitivity
of mismatch-repair-deficient cells to bulky rhodium(III) interca-
lators. Proc. Natl. Acad. Sci. U.S.A. 103, 15359–15363.
FIGURE 5: Effect of modulating the plasma membrane potential on
Ru(DIP)2dppz2+ cellular uptake determined by flow cytometry.
HeLa cells were incubated with 2 µM Ru(DIP)2dppz2+ in Hanks’
balanced salt solution (HBSS), HBSS with valinomycin (hyperpo-
larizes), or K+-HBSS (depolarizes).
Cellular Uptake of Ruthenium Polypyridyls Biochemistry, Vol. 47, No. 45, 2008 11715
4. Sai, Y., and Tsuji, A. (2004) Transporter-mediated drug delivery:
recent progress and experimental approaches. Drug DiscoVery
Today 9, 712–720.
5. Li, H., and Qian, Z. M. (2002) Transferrin/transferrin receptor-
mediated drug delivery. Med. Res. ReV. 22, 225–250.
6. Puckett, C. A., and Barton, J. K. (2007) Methods to explore cellular
uptake of ruthenium complexes. J. Am. Chem. Soc. 129, 46–47.
7. Dwyer, F. P., Gyarfas, E. C., Rogers, W. P., and Koch, J. H. (1952)
Biological activity of complex ions. Nature 170, 190–191.
8. Clark, M. J. (2003) Ruthenium metallopharmaceuticals. Coord.
Chem. ReV. 236, 209–233.
9. Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B.,
Zorbas,H.,andKeppler,B.K.(2006)Frombenchtobedsidespreclinical
and early clinical development of the anticancer agent indazolium
trans-[tetrachlorobis(1H-indazole)ruthenate(III)](KP1019 or FFC14A).
J. Inorg. Biochem. 100, 891–904.
10. Bergamo, A., and Sava, G. (2007) Ruthenium complexes can
target determinants of tumour malignancy. Dalton Trans. 1267–
1272.
11. Zeglis, B. M., Pierre, V. C., and Barton, J. K. (2007) Metallo-
intercalators and metallo-insertors. Chem. Commun., 4565–4579.
12. Ross, M. F., Kelso, G. F., Blaikie, F. H., James, A. M., Cocheme,
H. M., Filipovska, A., Da Ros, T., Hurd, T. R., Smith, R. A. J.,
and Murphy, M. P. (2005) Lipophilic triphenylphosphonium cations
as tools in mitochondrial bioenergetics and free radical biology.
Biochemistry (Moscow) 70, 222–230.
13. Davis, S., Weiss, M. J., Wong, J. R., Lampidis, T. J., and Chen,
L. B. (1985) Mitochondrial and plasma membrane potentials cause
unusual accumulation and retention of rhodamine 123 by human
breast adenocarcinoma-derived MCF-7 cells. J. Biol. Chem. 260,
13844–13850.
14. Sullivan, B. P., Salmon, D. J., and Meyer, T. J. (1978) Mixed
phosphine 2,2′-bipyridine complexes of ruthenium. Inorg. Chem.
17, 3334–3341.
15. Dickeson, J. E., and Summers, L. A. (1970) Derivatives of 1,10-
phenanthroline-5,6-quinone. Aust. J. Chem. 23, 1023–1027.
16. Bleil, J. D., and Bretscher, M. S. (1982) Transferrin receptor and
its recycling in HeLa cells. EMBO J. 1, 351–355.
17. Friedman, A. E., Chambron, J.-C., Sauvage, J.-P., Turro, N. J.,
and Barton, J. K. (1990) Molecular “light switch” for DNA:
Ru(bpy) 2dppz2+. J. Am. Chem. Soc. 112, 4960–4962.
18. Jenkins, Y., Friedman, A. E., Turro, N. J., and Barton, J. K. (1992)
Characterization of dipyridophenazine complexes of ruthenium(II):
the light switch effect as a function of nucleic acid sequence and
conformation. Biochemistry 31, 10809–10816.
19. Wheatley, D. N., Inglis, M. S., Foster, M. A., and Rimington, J. E.
(1987) Hydration, volume changes and nuclear magnetic resonance
proton relaxation times of HeLa S-3 cells in M-phase and the
subsequent cell cycle. J. Cell Sci. 88, 13–23.
20. Schmid, S. L., and Carter, L. L. (1990) ATP is required for receptor-
mediated endocytosis in intact cells. J. Cell Biol. 111, 2307–2318.
21. Barban, S., and Schulze, H. (1961) The effects of 2-deoxyglucose
on the growth and metabolism of cultured human cells. J. Biol.
Chem. 236, 1887–1890.
22. Slater, E. C. (1967) Application of inhibitors and uncouplers for a
study of oxidative phosphorylation. Methods Enzymol. 10, 48–57.
23. Koepsell, H. (2004) Polyspecific organic cation transporters: their
functions and interactions with drugs. Trends Pharmacol. Sci. 25,
375–381.
24. Wu, X., Prasad, P. D., Leibach, F. H., and Ganapathy, V. (1998)
cDNA sequence, transport function, and genomic organization of
human OCTN2, a new member of the organic cation transporter
family. Biochem. Biophys. Res. Commun. 246, 589–595.
25. Koepsell, H., Lips, K., and Volk, C. (2007) Polyspecific organic
cation transporters: structure, function, physiological roles, and
biopharmaceutical implications. Pharmacol. Res. 24, 1227–1251.
26. Lodish, H., Berk, A., Zipursky, S. L., Matsudaira, P., Baltimore,
D., and Darnell, J. E. (2000) Molecular Cell Biology, 4th ed., W. H.
Freeman, New York.
27. Ehrenberg, B., Montana, V., Wei, M.-D., Wuskell, J. P., and Loew,
L. M. (1988) Membrane potential can be determined in individual
cells from the Nernstian distribution of cationic dyes. Biophys. J.
53, 785–794.
28. Shapiro, H. M. (2000) Membrane potential estimation by flow
cytometry. Methods 21, 271–279.
BI800856T
11716 Biochemistry, Vol. 47, No. 45, 2008 Puckett and Barton
